Dasiglucagon
Also known as: dasiglucagon, stable glucagon analog, Zegalogue, ZP4207
Source Dasiglucagon at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Dasiglucagon is a stable glucagon analog formulated for subcutaneous injection, used as a rescue treatment for severe hypoglycemia in patients with diabetes.
Mechanism of Action
Activates the glucagon receptor, stimulating hepatic glycogenolysis and gluconeogenesis to raise blood glucose.
Routes of Administration
Goals & Uses
- Severe hypoglycemia rescueGlycemic Emergency ManagementHigh
- Hypoglycemia treatment in congenital hyperinsulinismEndocrine Disorder ManagementModerate
- Prevention of exercise-induced hypoglycemiaHypoglycemia PreventionLow
Contraindications
- Prolonged fasting or starvationNutritionalModerate
- Known hypersensitivity to dasiglucagon or excipientsAllergyHigh
- InsulinomaEndocrine TumorModerate
- PheochromocytomaEndocrine TumorHigh
- GlucagonomaEndocrine TumorHigh
- Hypersensitivity to dasiglucagon or excipientsAllergyHigh
Adverse Effects
- HypertensionCardiovascularUncommonHigh blood pressure
- Injection site reactionsLocalCommon
- Injection site painLocalCommonPain at the injection site
- Hypersensitivity/anaphylaxisImmunologicalRare
- HeadacheNeurologicCommonPain in the head or upper neck
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- VomitingGastrointestinalCommonForceful expulsion of stomach contents
Drug Interactions
- InsulinLowMay increase risk of low blood sugar
- Beta‑blockersModerate
- Beta-blockersModerate
- WarfarinModerate
- Other glucagon receptor agonistsModerate
Population Constraints
- PregnancyReproductive SafetyRelative
- Hepatic impairmentOrgan FunctionRelative
- Adrenal insufficiencyEndocrineRelative
- Age <2 yearsPediatricAbsolute
- Children under 6 years of agePediatricAbsolute
Regulatory Status
- European UnionUnapprovedPending evaluation; not yet authorized.
- United StatesApprovedApproved: Severe hypoglycemia in diabetes (≥2 years)Approved as Zegalogue, subcutaneous injection.
- United KingdomUnknownPost-Brexit regulatory status uncertain; approval may follow EU decision via MHRA.
FDA‑approved (2021) as Zegalogue for patients ≥2 years; not yet approved in the EU.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Dasiglucagon?
Dasiglucagon is a stable glucagon analog formulated for subcutaneous injection, used as a rescue treatment for severe hypoglycemia in patients with diabetes.
What is Dasiglucagon used for?
Dasiglucagon is educationally associated with: Severe hypoglycemia rescue, Hypoglycemia treatment in congenital hyperinsulinism, Prevention of exercise-induced hypoglycemia. Educational only — not medical advice.
How is Dasiglucagon administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Dasiglucagon?
Reported adverse effects include: Hypertension, Injection site reactions, Injection site pain, Hypersensitivity/anaphylaxis, Headache, Nausea, Vomiting. This list is not exhaustive — consult a qualified clinician.
Who should avoid Dasiglucagon?
Recorded contraindications: Prolonged fasting or starvation, Known hypersensitivity to dasiglucagon or excipients, Insulinoma, Pheochromocytoma, Glucagonoma, Hypersensitivity to dasiglucagon or excipients. Consult a qualified clinician before use.